Cancer immunotherapy: dawn of the death of cancer?

References

• Cooper GM, Hausman RE. The Cell: A Molecular Approach. 4th ed. USA: Sinauer Associates; 2007.
   Google Scholar
• Lodish H, Berk A, Zipursky SL, Matsudira P, Baltimore D, Darnell JE. Molecular Cell Biology. 5th ed. W. H. Freeman. USA. 2003: 973.
   Google Scholar
• Owen JA, Punt J, Stranford SA. Kuby Immunology. 7th ed. Susan Winslow. New York, USA. 2013: 692.
   Google Scholar
• Butterfield LH. Cancer vaccines. BMJ. 2015;350:h988 doi:10.1136/bmj.h988.
   PubMed Web of Science ®Google Scholar
• Sudhakar A. History of cancer, ancient and modern treatment methods. J Cancer Sci Ther. 2009;1(2):1–4. doi:10.4172/1948-5956.100000e2.
   PubMedGoogle Scholar
• Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012;62(5):309–335. doi:10.3322/caac.20132.
   PubMed Web of Science ®Google Scholar
• Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342(6165):1432–1433. doi:10.1126/science.342.6165.1432.
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278–287. doi:10.1038/nrc3236.
   PubMed Web of Science ®Google Scholar
• Perica K, Varela JC, Oelke M, Schneck J. Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med J. 2015;6(1):e0004 doi:10.5041/RMMJ.10179.
   PubMed Web of Science ®Google Scholar
• Almåsbak H, Aarvak T, Vemuri MC. CAR T cell therapy: a game changer in cancer treatment. J Immunol Res. 2016;2016:5474602 doi:10.1155/2016/5474602.
   PubMed Web of Science ®Google Scholar
• Yang J, Zhang Q, Li K, Yin H, Zheng JN. Composite peptide-based vaccines for cancer immunotherapy (Review). Int J Mol Med. 2015;35(1):17–23. doi:10.3892/ijmm.2014.2000.
   PubMed Web of Science ®Google Scholar
• Vigneron N. Human tumor antigens and cancer immunotherapy. Biomed Res Int. 2015;2015:948501 doi:10.1155/2015/948501.
   PubMed Web of Science ®Google Scholar
• Liu CC, Ye XS. Carbohydrate-based cancer vaccines: target cancer with sugar bullets. Glycoconj J. 2012;29(5–6):259–271. doi:10.1007/s10719-012-9399-9.
   PubMed Web of Science ®Google Scholar
• Jiang T, Shi T, Zhang H, et al. Tumor neoantigens: from basic research to clinical applications. J Hematol Oncol. 2019;12(1):93 doi:10.1186/s13045-019-0787-5.
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838–1847. doi:10.1056/NEJMoa0810097.
   PubMed Web of Science ®Google Scholar
• Robbins PF, El-Gamil M, Li YF, et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med. 1996;183(3):1185–1192. doi:10.1084/jem.183.3.1185.
   PubMed Web of Science ®Google Scholar
• Bocchia M, Wentworth PA, Southwood S, et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood. 1995;85(10):2680–2684. doi:10.1182/blood.V85.10.2680.bloodjournal85102680.
   PubMed Web of Science ®Google Scholar
• Slingluff CL. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J. 2011;17(5):343–350. doi:10.1097/PPO.0b013e318233e5b2.
   PubMed Web of Science ®Google Scholar
• Lazoura E, Apostolopoulos V. Insights into peptide-based vaccine design for cancer immunotherapy. Curr Med Chem. 2005;12(13):1481–1494. doi:10.2174/0929867054039017.
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci Usa. 1994;91(14):6458–6462. doi:10.1073/pnas.91.14.6458.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4(3):321–327. doi:10.1038/nm0398-321.
   PubMed Web of Science ®Google Scholar
• Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 1996;56(20):4749–4757.
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119–2127. doi:10.1056/NEJMoa1012863.
   PubMed Web of Science ®Google Scholar
• Criscitiello C. Tumor-associated antigens in breast cancer. Breast Care (Basel)). 2012;7(4):262–266. doi:10.1159/000342164.
   PubMed Web of Science ®Google Scholar
• Peres LP, da Luz FA, Pultz BA, et al. Peptide vaccines in breast cancer: the immunological basis for clinical response. Biotechnol Adv. 2015;33(8):1868–1877. doi:10.1016/j.biotechadv.2015.10.013.
   PubMed Web of Science ®Google Scholar
• Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol. 2002;20(11):2624–2632. doi:10.1200/JCO.2002.06.171.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Clifton GT, Holmes JP, et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol. 2014;25(9):1735–1742. doi:10.1093/annonc/mdu211.
   PubMed Web of Science ®Google Scholar
• Palucka K, Ueno H, Fay J, Banchereau J. Dendritic cells and immunity against cancer. J Intern Med. 2011;269(1):64–73. doi:10.1111/j.1365-2796.2010.02317.x.
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013;39(1):38–48. doi:10.1016/j.immuni.2013.07.004.
   PubMed Web of Science ®Google Scholar
• Kirk CJ, Mulé JJ. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther. 2000;11(6):797–806. doi:10.1089/10430340050015419.
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Comin-Anduix B, Vujanovic L, et al. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother. 2008;31(3):294–309. doi:10.1097/CJI.0b013e31816a8910.
   PubMed Web of Science ®Google Scholar
• Van Tendeloo VF, Van de Velde A, Van Driessche A, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci Usa. 2010;107(31):13824–13829. doi:10.1073/pnas.1008051107.
   PubMed Web of Science ®Google Scholar
• Galati D, Zanotta S. Hematologic neoplasms: dendritic cells vaccines in motion. Clin Immunol. 2017;183:181–190. doi:10.1016/j.clim.2017.08.016.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vacchelli E, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology. 2012;1(7):1111–1134. doi:10.4161/onci.21494.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Vitale I, Eggermont A, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology. 2013;2(10):e25771 doi:10.4161/onci.25771.
   PubMed Web of Science ®Google Scholar
• Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci Usa. 1998;95(22):13141–13146. doi:10.1073/pnas.95.22.13141.
   PubMed Web of Science ®Google Scholar
• Luiten RM, Kueter EW, Mooi W, et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol. 2005;23(35):8978–8991. doi:10.1200/JCO.2005.01.6816.
   PubMed Web of Science ®Google Scholar
• Chakraborty NG, Sporn JR, Tortora AF, et al. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol Immunother. 1998;47(1):58–64. doi:10.1007/s002620050504.
   PubMed Web of Science ®Google Scholar
• Geiger J, Hutchinson R, Hohenkirk L, McKenna E, Chang A, Mulé J. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet. 2000;356(9236):1163–1165. doi:10.1016/S0140-6736(00)02762-8.
   PubMed Web of Science ®Google Scholar
• Polyzoidis S, Ashkan K. DCVax®-L-developed by Northwest Biotherapeutics. Hum Vaccin Immunother. 2014;10(11):3139–3145. doi:10.4161/hv.29276.
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Economou JS, Gamblin TC, Geller DA. Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. J Transl Med. 2014;12:86 doi:10.1186/1479-5876-12-86.
   PubMed Web of Science ®Google Scholar
• Santiago-Ortiz JL, Schaffer DV. Adeno-associated virus (AAV) vectors in cancer gene therapy. J Control Release. 2016;240:287–301. doi:10.1016/j.jconrel.2016.01.001.
   PubMed Web of Science ®Google Scholar
• Pol J, Bloy N, Obrist F, et al. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology. 2014;3(1):e28185 doi:10.4161/onci.28185.
   PubMed Web of Science ®Google Scholar
• Wilcox ME, Yang W, Senger D, et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. Journal of the National Cancer Institute. 2001;93(12):903–912. doi:10.1093/jnci/93.12.903.
   PubMedGoogle Scholar
• Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658–670. doi:10.1038/nbt.2287.
   PubMed Web of Science ®Google Scholar
• Ko D, Hawkins L, Yu DC. Development of transcriptionally regulated oncolytic adenoviruses. Oncogene. 2005;24(52):7763–7774. doi:10.1038/sj.onc.1209048.
   PubMed Web of Science ®Google Scholar
• Russell SJ, Peng KW. Viruses as anticancer drugs. Trends Pharmacol Sci. 2007;28(7):326–333. doi:10.1016/j.tips.2007.05.005.
   PubMed Web of Science ®Google Scholar
• Heiniö C, Havunen R, Santos J, et al. TNFa and IL2 encoding oncolytic adenovirus activates pathogen and danger-associated immunological signaling. Cells. 2020;9(4):798. doi:10.3390/cells9040798.
   PubMed Web of Science ®Google Scholar
• Poutou J, Bunuales M, Gonzalez-Aparicio M, et al. Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model. Gene Ther. 2015;22(9):696–706. doi:10.1038/gt.2015.45.
   PubMed Web of Science ®Google Scholar
• Nguyen HM, Guz-Montgomery K, Saha D. Oncolytic Virus encoding a master pro-inflammatory cytokine interleukin 12 in cancer immunotherapy. Cells. 2020;9(2):400. doi:10.3390/cells9020400.
   Web of Science ®Google Scholar
• Wang G, Kang X, Chen KS, et al. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat Commun. 2020;11(1):1395 doi:10.1038/s41467-020-15229-5.
   PubMed Web of Science ®Google Scholar
• Eissa IR, Bustos-Villalobos I, Ichinose T, et al. The current status and future prospects of oncolytic viruses in clinical trials against melanoma, glioma, pancreatic, and breast cancers. Cancers. 2018;10(10):356. doi:10.3390/cancers10100356.
   Web of Science ®Google Scholar
• Zhu Z, Gorman MJ, McKenzie LD, et al. Zika virus has oncolytic activity against glioblastoma stem cells. J Exp Med. 2017;214(10):2843–2857. doi:10.1084/jem.20171093.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Mesci P, Bernatchez JA, et al. Zika Virus Targets Glioblastoma Stem Cells through a SOX2-Integrin αvβ5 Axis. Cell Stem Cell. 2020;26(2):187–204.e10. doi:10.1016/j.stem.2019.11.016.
   PubMed Web of Science ®Google Scholar
• McNamara MA, Nair SK, Holl EK. RNA-based vaccines in cancer immunotherapy. J Immunol Res. 2015;2015:794528 doi:10.1155/2015/794528.
   PubMed Web of Science ®Google Scholar
• Tiptiri-Kourpeti A, Spyridopoulou K, Pappa A, Chlichlia K. DNA vaccines to attack cancer: strategies for improving immunogenicity and efficacy. Pharmacol Ther. 2016;165:32–49. doi:10.1016/j.pharmthera.2016.05.004.
   PubMed Web of Science ®Google Scholar
• Ahmad S, Casey G, Sweeney P, Tangney M, O’Sullivan GC. Optimised electroporation mediated DNA vaccination for treatment of prostate cancer. Genet Vaccines Ther. 2010;8(1):1. doi:10.1186/1479-0556-8-1.
   PubMedGoogle Scholar
• Staff C, Mozaffari F, Haller BK, Wahren B, Liljefors M. A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients. Vaccine. 2011;29(39):6817–6822. doi:10.1016/j.vaccine.2010.12.063.
   PubMed Web of Science ®Google Scholar
• Abraham RS, Mitchell DA. Gene-modified dendritic cell vaccines for cancer. Cytotherapy. 2016;18(11):1446–1455. doi:10.1016/j.jcyt.2016.09.009.
   PubMed Web of Science ®Google Scholar
• Heiser A, Coleman D, Dannull J, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest. 2002;109(3):409–417. doi:10.1172/JCI0214364.
   PubMed Web of Science ®Google Scholar
• Bloy N, Buqué A, Aranda F, et al. Trial watch: naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 2015;4(5):e1026531 doi:10.1080/2162402X.2015.1026531.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422. doi:10.1056/NEJMoa1001294.
   PubMed Web of Science ®Google Scholar
• Paller CJ, Antonarakis ES. Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges. Hum Vaccin Immunother. 2012;8(4):509–519. doi:10.4161/hv.18860.
   PubMed Web of Science ®Google Scholar
• Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology. 2016;5(1):e1115641 doi:10.1080/2162402X.2015.1115641.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Packard BS, Aebersold PM, Solomon D, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676–1680. doi:10.1056/NEJM198812223192527.
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005;202(7):907–912. doi:10.1084/jem.20050732.
   PubMed Web of Science ®Google Scholar
• Besser MJ, Shapira-Frommer R, Itzhaki O, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res. 2013;19(17):4792–4800. doi:10.1158/1078-0432.CCR-13-0380.
   PubMed Web of Science ®Google Scholar
• Andersen R, Donia M, Ellebaek E, et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin Cancer Res. 2016;22(15):3734–3745. doi:10.1158/1078-0432.CCR-15-1879.
   PubMed Web of Science ®Google Scholar
• Baruch EN, Berg AL, Besser MJ, Schachter J, Markel G. Adoptive T cell therapy: an overview of obstacles and opportunities. Cancer. 2017;123(S11):2154–2162. doi:10.1002/cncr.30491.
   PubMedGoogle Scholar
• Yun CO, Nolan KF, Beecham EJ, Reisfeld RA, Junghans RP. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia. 2000;2(5):449–459. doi:10.1038/sj.neo.7900108.
   PubMed Web of Science ®Google Scholar
• Hollyman D, Stefanski J, Przybylowski M, et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 2009;32(2):169–180. doi:10.1097/CJI.0b013e318194a6e8.
   PubMed Web of Science ®Google Scholar
• Maus MV, June CH. Making better chimeric antigen receptors for adoptive T-cell therapy. Clin Cancer Res. 2016;22(8):1875–1884. doi:10.1158/1078-0432.CCR-15-1433.
   PubMed Web of Science ®Google Scholar
• Park JH, Brentjens RJ. Are all chimeric antigen receptors created equal? J Clin Oncol. 2015;33(6):651–653. doi:10.1200/JCO.2014.57.5472.
   PubMed Web of Science ®Google Scholar
• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci Usa. 1989;86(24):10024–10028. doi:10.1073/pnas.86.24.10024.
   PubMed Web of Science ®Google Scholar
• Hwu P, Shafer GE, Treisman J, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med. 1993;178(1):361–366. doi:10.1084/jem.178.1.361.
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Hwu P. Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol. 2002;20(12):1221–1227. doi:10.1038/nbt756.
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12(20 Pt 1):6106–6115. doi:10.1158/1078-0432.CCR-06-1183.
   PubMed Web of Science ®Google Scholar
• Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006;66(22):10995–11004. doi:10.1158/0008-5472.CAN-06-0160.
   PubMed Web of Science ®Google Scholar
• Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453–1464. doi:10.1038/mt.2009.83.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145–1154. doi:10.1517/14712598.2015.1046430.
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25 doi:10.1126/scitranslmed.3008226.
   PubMed Web of Science ®Google Scholar
• Kakarla S, Gottschalk S. CAR T cells for solid tumors: armed and ready to go? Cancer J. 2014;20(2):151–155. doi:10.1097/PPO.0000000000000032.
   PubMed Web of Science ®Google Scholar
• Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–497. doi:10.1038/256495a0.
   PubMed Web of Science ®Google Scholar
• Coulson A, Levy A, Gossell-Williams M. Monoclonal antibodies in cancer therapy: mechanisms, successes and limitations. West Indian Med J. 2014;63(6):650–654. doi:10.7727/wimj.2013.241.
   PubMed Web of Science ®Google Scholar
• Vaklavas C, Forero-Torres A. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol. 2012;3(4):209–225. doi:10.1177/2040620712443076.
   PubMedGoogle Scholar
• Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96(4):1259–1266.
   PubMed Web of Science ®Google Scholar
• Nguyen TH, Havari E, McLaren R, et al. Alemtuzumab induction of intracellular signaling and apoptosis in malignant B lymphocytes. Leuk Lymphoma. 2012;53(4):699–709. doi:10.3109/10428194.2011.623253.
   PubMed Web of Science ®Google Scholar
• Lynce F, Swain SM. Pertuzumab for the treatment of breast cancer. Cancer Invest. 2014;32(8):430–438. doi:10.3109/07357907.2014.922570.
   PubMed Web of Science ®Google Scholar
• Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23(9):1147–1157. doi:10.1038/nbt1137.
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47(2):115–123. doi:10.1053/j.seminhematol.2010.01.011.
   PubMed Web of Science ®Google Scholar
• Seimetz D. Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab). J Cancer. 2011;2:309–316. doi:10.7150/jca.2.309.
   PubMed Web of Science ®Google Scholar
• Hörl S, Banki Z, Huber G, et al. Complement factor H-derived short consensus repeat 18–20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells. Haematologica. 2013;98(12):1939–1947. doi:10.3324/haematol.2013.089615.
   PubMed Web of Science ®Google Scholar
• Miotti S, Canevari S, Ménard S, et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer. 1987;39(3):297–303. doi:10.1002/ijc.2910390306.
   PubMed Web of Science ®Google Scholar
• Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825–830. doi:10.1097/CJI.0b013e318156e47e.
   PubMed Web of Science ®Google Scholar
• Callahan MK, Postow MA, Wolchok JD. Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol. 2013;31(2):191–199. doi:10.1016/j.clindermatol.2012.08.006.
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10(2):145–147. doi:10.1038/nm988.
   PubMed Web of Science ®Google Scholar
• Tsumoto K, Isozaki Y, Yagami H, Tomita M. Future perspectives of therapeutic monoclonal antibodies. Immunotherapy. 2019;11(2):119–127. doi:10.2217/imt-2018-0130.
   PubMed Web of Science ®Google Scholar
• Yonesaka K, Zejnullahu K, Okamoto I, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011;3(99):99ra86 doi:10.1126/scitranslmed.3002442.
   PubMed Web of Science ®Google Scholar
• Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006;3(5):269–280. doi:10.1038/ncponc0509.
   PubMedGoogle Scholar
• Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog. 2012;17(1):1–16. doi:10.1615/critrevoncog.v17.i1.20.
   PubMedGoogle Scholar
• Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol. 1997;15(2):159–163. doi:10.1038/nbt0297-159.
   PubMed Web of Science ®Google Scholar
• Fournier P, Schirrmacher V. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future. BioDrugs. 2013;27(1):35–53. doi:10.1007/s40259-012-0008-z.
   PubMed Web of Science ®Google Scholar
• Weidle UH, Tiefenthaler G, Weiss EH, Georges G, Brinkmann U. The intriguing options of multispecific antibody formats for treatment of cancer. Cancer Genomics Proteomics. 2013;10(1):1–18.
   PubMed Web of Science ®Google Scholar
• Jachimowicz RD, Borchmann S, Rothe A. Multi-specific antibodies for cancer immunotherapy. BioDrugs. 2014;28(4):331–343. doi:10.1007/s40259-014-0091-4.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA. 2003;100(8):4712–4717. doi:10.1073/pnas.0830997100.
   PubMed Web of Science ®Google Scholar
• Contardi E, Palmisano GL, Tazzari PL, et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer. 2005;117(4):538–550. doi:10.1002/ijc.21155.
   PubMed Web of Science ®Google Scholar
• Tseng SY, Otsuji M, Gorski K, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med. 2001;193(7):839–846. doi:10.1084/jem.193.7.839.
   PubMed Web of Science ®Google Scholar
• Lote H, Cafferkey C, Chau I. PD-1 and PD-L1 blockade in gastrointestinal malignancies. Cancer Treat Rev. 2015;41(10):893–903. doi:10.1016/j.ctrv.2015.09.004.
   PubMed Web of Science ®Google Scholar
• Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24–33. doi:10.1016/j.molmed.2014.10.009.
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol. 2015;42(4):587–600. doi:10.1053/j.seminoncol.2015.05.013.
   PubMed Web of Science ®Google Scholar
• Swaika A, Hammond WA, Joseph RW. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol. 2015;67(2 Pt A):4–17. doi:10.1016/j.molimm.2015.02.009.
   PubMed Web of Science ®Google Scholar
• Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013;94(1):41–53. doi:10.1189/jlb.1212631.
   PubMed Web of Science ®Google Scholar
• Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015;35:76–83. doi:10.14694/EdBook_AM.2015.35.76.
   PubMedGoogle Scholar
• Assal A, Kaner J, Pendurti G, Zang X. Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy. 2015;7(11):1169–1186. doi:10.2217/imt.15.78.
   PubMed Web of Science ®Google Scholar
• Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73 doi:10.1186/s12916-016-0623-5.
   PubMed Web of Science ®Google Scholar
• Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14(8):561–584. doi:10.1038/nrd4591.
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526. doi:10.1056/NEJMoa1104621.
   PubMed Web of Science ®Google Scholar
• Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–712. doi:10.1016/S1470-2045(14)70189-5.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol. 2011;29(36):4828–4836. doi:10.1200/JCO.2011.38.0899.
   PubMed Web of Science ®Google Scholar
• Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci Usa. 2010;107(9):4275–4280. doi:10.1073/pnas.0915174107.
   PubMed Web of Science ®Google Scholar
• Das R, Verma R, Sznol M, et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol. 2015;194(3):950–959. doi:10.4049/jimmunol.1401686.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–133. doi:10.1056/NEJMoa1302369.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi:10.1016/j.immuni.2013.07.012.
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013;73(12):3591–3603. doi:10.1158/0008-5472.CAN-12-4100.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi:10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Emens LA. Cancer vaccines: on the threshold of success. Expert Opin Emerg Drugs. 2008;13(2):295–308. doi:10.1517/14728214.13.2.295.
   PubMed Web of Science ®Google Scholar
• Graff JN, Chamberlain ED. Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy. Core Evid. 2015;10:1–10. doi:10.2147/CE.S54712.
   PubMed Web of Science ®Google Scholar
• Yaddanapudi K, Mitchell RA, Eaton JW. Cancer vaccines: looking to the future. Oncoimmunology. 2013;2(3):e23403 doi:10.4161/onci.23403.
   PubMed Web of Science ®Google Scholar
• Yee C. Adoptive T cell therapy: addressing challenges in cancer immunotherapy. J Transl Med. 2005;3(1):17doi:10.1186/1479-5876-3-17.
   PubMedGoogle Scholar
• Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843–851. doi:10.1038/mt.2010.24.
   PubMed Web of Science ®Google Scholar
• Choi D, Kim TG, Sung YC. The past, present, and future of adoptive T cell therapy. Immune Netw. 2012;12(4):139–147. doi:10.4110/in.2012.12.4.139.
   PubMedGoogle Scholar
• Worcester S. CAR T-cell therapy: Moving from cost to value 2017. 2017. https://www.mdedge.com/hematologynews/article/152563/all-acute-lymphoblastic-leukemia/car-t-cell-therapy-moving-cost-value. Published November 21, 2017. Accessed November 8, 2018.
   Google Scholar
• Qi WX, Fu S, Zhang Q, Guo XM. Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis. BMC Med. 2014;12(1):203. doi:10.1186/s12916-014-0203-5.
   PubMed Web of Science ®Google Scholar
• Riedell P, Carson KR. A drug safety evaluation of rituximab and risk of hepatitis B. Expert Opin Drug Saf. 2014;13(7):977–987. doi:10.1517/14740338.2014.918948.
   PubMed Web of Science ®Google Scholar
• Simpson A, Caballero O. Monoclonal antibodies for the therapy of cancer. BMC Proceedings. 2014;8(Suppl 4):O6. https://doi.org/10.1186/1753-6561-8-S4-O6
   Google Scholar
• Geynisman DM, Chien CR, Smieliauskas F, Shen C, Shih YC. Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review. Hum Vaccin Immunother. 2014;10(11):3415–3424. doi:10.4161/hv.29407.
   PubMed Web of Science ®Google Scholar
• Verma V, Sprave T, Haque W, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunotherapy Cancer. 2018;6:128.
   PubMed Web of Science ®Google Scholar
• Anassi E, Ndefo UA. Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. PT. 2011;36(4):197–202.
   PubMedGoogle Scholar
• Caram M, Ross R, Lin P, Mukherjee B. Factors associated with use of Sipuleucel-T to treat patients with advanced prostate cancer. JAMA Netw Open. 2019;2(4):e192589 doi:10.1001/jamanetworkopen.2019.2589.
   PubMed Web of Science ®Google Scholar
• Gong CL, Hay JW. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer. J Natl Compr Canc Netw. 2014;12(10):1417–‐1425. doi:10.6004/jnccn.2014.0139.
   PubMed Web of Science ®Google Scholar
• Chopra R, Lopes G. Improving Access to Cancer Treatments: The Role of Biosimilars. J Glob Oncol. 2017;3(5):596–610. doi:10.1200/JGO.2016.008607.
   PubMed Web of Science ®Google Scholar
• Amos SM, Duong CP, Westwood JA, et al. Autoimmunity associated with immunotherapy of cancer. Blood. 2011;118(3):499–509. doi:10.1182/blood-2011-01-325266.
   PubMed Web of Science ®Google Scholar
• Dores GM, Bryant-Genevier M, Perez-Vilar S. Adverse events associated with the use of Sipuleucel-T reported to the US food and drug administration's adverse event reporting system, 2010-2017. JAMA Netw Open. 2019;2(8):e199249 doi:10.1001/jamanetworkopen.2019.9249.
   PubMed Web of Science ®Google Scholar
• Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45–45. doi:10.1016/j.blre.2018.11.002.
   PubMed Web of Science ®Google Scholar
• Alatrash G, Jakher H, Stafford PD, Mittendorf EA. Cancer immunotherapies, their safety and toxicity. Expert Opin Drug Saf. 2013;12(5):631–645. doi:10.1517/14740338.2013.795944.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95.
   PubMed Web of Science ®Google Scholar
• Martinez P, Peters S, Stammers T, Soria JC. Immunotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25(9):2691–2698. doi:10.1158/1078-0432.CCR-18-3904.
   PubMed Web of Science ®Google Scholar
• Kalani AD, Jack A, Montenegro G, Degliuomini J, Wallack MK. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma. G Ital Dermatol Venereol. 2008;143(1):59–70.
   PubMedGoogle Scholar
• Spencer KR, Wang J, Silk AW, Ganesan S, Kaufman HL, Mehnert JM. Biomarkers for Immunotherapy: Current Developments and Challenges. Am Soc Clin Oncol Educ Book. 2016;35:e493–‐503. doi:10.1200/EDBK_160766.
   PubMedGoogle Scholar
• Jilg S, Rassner M, Maier J, et al. Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST). Int J Cancer. 2019;145(8):2292–2303. doi:10.1002/ijc.32282.
   PubMed Web of Science ®Google Scholar
• Costantini A, Julie C, Dumenil C, et al. Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab. Oncoimmunology. 2018. 2018;7(8):e1452581 doi:10.1080/2162402X.2018.1452581.
   Google Scholar
• Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052–3061. doi:10.1158/0008-5472.CAN-09-3690.
   PubMed Web of Science ®Google Scholar
• Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res. 2012;72(14):3439–3444. doi:10.1158/0008-5472.CAN-11-3912.
   PubMed Web of Science ®Google Scholar